Aeterna Zentaris’ endometrial cancer drug fails in Phase III
A late stage clinical study of Aeterna Zentaris’ Zoptrex in women with locally advanced, recurrent or metastatic endometrial cancer has failed to meet its primary endpoint of demonstrating a statistically significant increase in survival in patients taking the drug.
Read More
